Sign in →

Test Code LAB0002027 Brivaracetam, Plasma

Additional Codes

Mayo Test ID
BRIVA


Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Lavender top (K2 EDTA)

Acceptable: Lavender top (K3 EDTA), green top (sodium or lithium heparin), light-blue top (sodium citrate)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Draw blood immediately before next scheduled dose.

2. For sustained-release formulations only, draw blood a minimum of 12 hours after last dose.

3. Within 2 hours of collection, centrifuge and aliquot plasma into a plastic vial.


Useful For

Assessing compliance and toxicity for brivaracetam

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

Brivaracetam, P

Specimen Type

Plasma EDTA

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma EDTA Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Reference Values

0.2-2.0 mcg/mL

Interpretation

The report is intended for use by a physician to determine if the patient is receiving a dose sufficient to achieve a therapeutic effect or to assess whether the patient is compliant with prescribed dose. The reference range represents the concentrations observed to be associated with greatest drug efficacy without side effects or toxicity.

 

Most individuals display optimal response to brivaracetam with plasma levels 0.2 to 2.0 mcg/mL. Some individuals may respond well outside of this range or may display toxicity within the therapeutic range; thus, interpretation should include clinical evaluation. Toxic levels have not been well established. Therapeutic ranges are based on specimens collected at trough (ie, immediately before the next dose).

Day(s) Performed

Monday through Friday

Report Available

Same day/1 to 2 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80299

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BRIVA Brivaracetam, P 88894-1

 

Result ID Test Result Name Result LOINC Value
620767 Brivaracetam, P 88894-1